Replies to post #63967 on Biotech Values

[Bio_pete]

re: JAV

Its my understanding that a lot of pressure has been placed on the new management to find a buy-out offer. They keep changing the game plan every few months, but this looks like the best case scenario. Top-line data on Dyloject's Phase III will be reported late 3rd qtr. The company will then hire a bank to solicit offers. If they can't find a buyer then it will look like another MBRK.

I predict the company will report less then $200K for Dyloject sales in the 2nd qtr & the stock may break $2 a share. The stock should trend back to the $2.50 area as we wait for Phase III data (extremely low chance of negative results) and may trade over $3.00 once the results are released.

[apljack]

Re: JAV

Bladerunner, I can't imagine mgmt trying to go it alone, particularly since they're on record about looking for partners and stating publicly that there has been an increase` in unsolicited interest from outside partners. Going it alone would mean they've failed miserably in getting a partner and would lose what limited credibility they currently have.

Biopete's post notwithstanding, I think that we will continue to bounce at this price range as mgmt buys at $2.41 in the recent private placement appears to have established the bottom. I agree with biopete that sales will come in light of the $220K estimate, but not by much. P3 data will see a boost in interest. I still believe that Dyloject will ultimately replace Toradol in most hospital practices and be a $200-300 million drug in a couple of years. PMI-150 will also find that type of market share for breakthrough pain, both in post-op and cancer settings.

Downside here is minimal, I'd be buying if I had some spare cash.

aj